We are live on ! Find out more
UTHR icon

United Therapeutics
UTHR

461 hedge funds and large institutions have $9.45B invested in United Therapeutics in 2022 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 170 increasing their positions, 160 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

104% more call options, than puts

Call options by funds: $104M | Put options by funds: $51M

2.74% more ownership

Funds ownership: 97.2% → 99.94% (+2.7%)

6% more repeat investments, than reductions

Existing positions increased: 170 | Existing positions reduced: 160

2% less funds holding

Funds holding: 472 → 461 (-11)

9% less capital invested

Capital invested by funds: $10.3B → $9.45B (-$878M)

11% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 61

25% less funds holding in top 10

Funds holding in top 10: 24 → 18 (-6)

Holders
461
Holders Change
-11
Holders Change %
-2.33%
% of All Funds
7.94%
Holding in Top 10
18
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-25%
% of All Funds
0.31%
New
54
Increased
170
Reduced
160
Closed
61
Calls
$104M
Puts
$51M
Net Calls
+$53.1M
Net Calls Change
+$3.64M

Top Buyers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$211M
2
Citadel Advisors
Citadel Advisors
Florida
+$124M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$63.7M
4
APM
Avidity Partners Management
Texas
+$54.7M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$36.6M

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$54.4M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$41.7M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$39M
4
American Century Companies
American Century Companies
Missouri
-$36.1M
5
First Trust Advisors
First Trust Advisors
Illinois
-$35.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
TFP
401
Tilia Fiduciary Partners
North Carolina
$19K – – –
HNB
402
Huntington National Bank
Ohio
$19K +$14.3K +64 +229%
APA
403
American Portfolios Advisors
New York
$17.4K +$16.8K +75 +938%
GRP
404
Global Retirement Partners
California
$17K +$1.34K +6 +9%
AA
405
Addison Advisors
Vermont
$16K – – –
CWC
406
Carolinas Wealth Consulting
North Carolina
$15K – – –
CI Investments Inc
407
CI Investments Inc
Ontario, Canada
$14K -$224 -1 -1%
BWM
408
BerganKDV Wealth Management
Minnesota
$13K – – –
CAM
409
ClariVest Asset Management
California
$13K – – –
VWM
410
Valley Wealth Managers
New Jersey
$12K -$17.7K -79 -57%
PTC
411
Private Trust Company
Ohio
$12K – – –
ST
412
Smithfield Trust
Pennsylvania
$11K – – –
TWA
413
TCI Wealth Advisors
Arizona
$11K +$894 +4 +8%
MPWT
414
MassMutual Private Wealth & Trust
Connecticut
$11K +$1.56K +7 +16%
EI
415
Ellevest Inc
New York
$11K +$3.58K +16 +42%
HIM
416
Hillsdale Investment Management
Ontario, Canada
$10K – – –
SWM
417
Sugarloaf Wealth Management
Georgia
$10K – – –
JWA
418
JFS Wealth Advisors
Pennsylvania
$8K -$5.14K -23 -38%
FF
419
FourThought Financial
Florida
$8K – – –
BIA
420
Bell Investment Advisors
California
$7K -$671 -3 -8%
CTC
421
Central Trust Company
Missouri
$7K – – –
TCM
422
Tradewinds Capital Management
Washington
$7K – – –
Bank of Montreal
423
Bank of Montreal
Ontario, Canada
$6.93K +$5.26M +23,543 +247%
ACM
424
AUA Capital Management
Pennsylvania
$6K -$1.12K -5 -14%
APC
425
Aspire Private Capital
North Carolina
$6K -$447 -2 -6%
15 16
17
18 19

UTHR Hedge Fund Activity: Q3 2022 in Review

461 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2022, worth a combined $9.45B — down 8.5% from $10.3B a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of UTHR and 54 opened new positions — a net loss of 7 holders — while 160 trimmed existing stakes and 170 added.

The largest buyer was Janus Henderson Group, adding an estimated $211M. The largest seller was Renaissance Technologies, cutting an estimated $54.4M.

  • 461 institutional investors held United Therapeutics (UTHR) as of Q3 2022, down from 472 in Q2 2022.
  • Funds reported $9.45B of United Therapeutics stock for Q3 2022, down 8.5% quarter-over-quarter.
  • 54 funds opened new United Therapeutics positions in Q3 2022 and 61 closed out, a net change of -7 holders.
  • The largest United Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $211M added.
  • The largest United Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $54.4M sold.

Based on aggregated 13F filings for Q3 2022.